Viral hemorrhagic fevers (VHFs) refer to a group of illnesses that are caused by several distinct families of viruses. In general, the term "viral hemorrhagic fever" is used to describe a severe multisystem syndrome (multisystem in that multiple organ systems in the body are affected). Characteristically, the overall vascular system is damaged, and the body's ability to regulate itself is impaired. These symptoms are often accompanied by hemorrhage (bleeding); however, the bleeding is itself rarely life-threatening. While some types of hemorrhagic fever viruses can cause relatively mild illnesses, many of these viruses cause severe, life-threatening disease.
The Centers for Disease Control and Prevention has developed a new diagnostic test to detect the presence of dengue virus in people with symptoms of dengue fever or dengue hemorrhagic fever. The test, called the CDC DENV-1-4 Real Time RT PCR Assay, has been authorized by the Food and Drug Administration for use in the United States and can be performed using equipment and supplies many public health laboratories already use to diagnose influenza.
While vaccines are perhaps medicine's most important success story, there is always room for improvement. Researchers at Oregon Health & Science University's Oregon National Primate Research Center (ONPRC) appear to have done just that.
Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment was administered two days post-infection, an accomplishment unmatched by any experimental therapy for these viruses to date.
Researchers at the University of Texas Medical Branch have developed the first accurate predictive model to differentiate between dengue fever (DF) and its more severe form, dengue hemorrhagic fever (DHF).
Ebola was first identified in 1976 in Sudan and Zaire, which is now the Democratic Republic of the Congo and Ebola fever kills more than 90% of the people it infects. Ebola is among the most lethal diseases known to humans, according to the World Health Organization.
Four companies are to develop broad-spectrum therapeutics-antibiotics, antivirals and an antitoxin-to prevent or treat diseases caused by multiple types of bacteria or viruses, under contracts awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
A U.S. research team has discovered a protein called Niemann-Pick C1 (NPC1), which they found was responsible for allowing Ebola virus to enter and replicate within cells.
Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protect against both rabies and the Ebola virus.
The spread of Dengue fever in northern Australia may be controlled by a bacterium that infects mosquitoes that harbor the virus, Australian and U.S. researchers report Aug. 25 in two papers published in the journal Nature.
Research published by two teams of Army scientists and collaborators has identified a cellular protein that plays a critical role in Ebola virus infection.
Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.
More than a decade of targeted Muscular Dystrophy Association-funded research, made possible as a result of generous public support of the MDA Labor Day Telethon and thousands of grass-roots special events, has today culminated in MDA providing financial assistance for the start of the first Phase 2 placebo-controlled, multiple dose efficacy, safety, tolerability and pharmacokinetics clinical trial of an exon-51 skipping drug, eteplirsen, as a potential therapy for Duchenne muscular dystrophy.
In a new development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.
Molecular and cell biologists at the University of Virginia Health System have discovered new information about how the Ebola virus works that could eventually lead to new drug treatments for the deadly virus.
The ten studies in this special issue document the substantial and growing burden of dengue in the Americas, Africa and Asia, and the burden of a chikungunya outbreak in India.
Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.
France's Sanofi-Pasteur, the world's largest vaccine maker, said Friday it hopes to introduce a dengue vaccine in 2014 to some high-risk nations, AlertNet reports. The vaccine is in the last stage of clinical testing in Australia, and the company said it hopes to produce 100 million doses of the vaccine annually, according to the news agency.
Canadian investigators have shown that a species of ebolavirus from Zaire that is highly virulent in humans can replicate in pigs, cause disease, and be transmitted to animals previously unexposed to the virus.
The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.